Redefining Breast Cancer and Treatment: A Deep Dive into the Business of Atossa Therapeutics

I was privileged to sit down with John Heerdink, Founder & Managing Director of Tribe Public, for a deep dive into the business of Atossa Therapeutics and its ‘pipeline in a product’ strategy in breast cancer.

I had an in-depth discussion with John about Atossa Therapeutics – how it came to be, the background and scientific foundations, our patents & clinical trial successes, the latest developments, our notable financial and capitalization positioning, and the possibility that upwards of 200,000 breast cancer cases per year could be prevented through our ‘pipeline in a product’ strategy.

This is a conversation worth listening to for the latest in Atossa Therapeutics’ innovative therapies to address unmet needs in breast cancer.

About Tribe Public:

Tribe Public’s complimentary worldwide webinars are efficient 30-minute events that seek to provide direct corporate access to leaders of companies in industries that you care about. The events consist of a quick introduction to management a 15-minute presentation, and a brief Q&A session where you may ask the questions you care about too. Tribe events are hosted by Advisor, Investor, Entrepreneur John F. Heerdink, Jr., the Managing Partner of Tribe Public LLC.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies